Drug Trial Radar · NCT04089631
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
Last checked: Nov 19, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
4,812
Planned (sponsor's estimate)
Start
Jun 26, 2020
Primary completion
Jun 2023
Study completion Jun 2026
Sponsor
- Lead sponsor
- Technische Universität DresdenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CIRCULATE study evaluates the adjuvant therapy in patients with colon cancer UICC stage II. The primary aim of the study is to compare the disease free survival in patients who are positive for postoperative circulating tumour DNA with vs. without capecitabine.
Conditions
- Colon Cancer Stage II
Interventions
CapecitabineDrug
6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free Survival (DFS)Time frame: for the primary endpoint after 154 events (approx. 60 months after study start)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik
Dresden, Saxony, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.